Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (241-250 of 323) with videos related to

Pageof 33
Sort By:
Blood Advances|January 18, 2024
Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemiaKris Richardson, Jorge J Castillo, Shayna R Sarosiek, et al.
Plos One|October 5, 2018
Profiling of circulating exosomal miRNAs in patients with Waldenström MacroglobulinemiaJuliette M Bouyssou, Chia-Jen Liu, Mark Bustoros, et al.
Blood|January 18, 2006
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemiaSteven P Treon, Morie A Gertz, Meletios Dimopoulos, et al.
The Lancet. Haematology|October 22, 2020
Consensus treatment recommendations from the tenth International Workshop for Waldenström MacroglobulinaemiaJorge J Castillo, Ranjana H Advani, Andrew R Branagan, et al.
Haematologica|June 24, 2021
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapyJoshua N Gustine, Shayna Sarosiek, Catherine A Flynn, et al.
British Journal of Haematology|February 18, 2009
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom MacroglobulinemiaXavier Leleu, Zachary R Hunter, Lian Xu, et al.
European Journal of Haematology|March 12, 2008
Clinical relevance of soluble HLA class I molecules in Waldenstrom MacroglobulinemiaAnne-Sophie Moreau, Yasmine Sebti, Alain Duhamel, et al.
Blood|April 26, 2024
High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemiaEric Durot, Damien Roos-Weil, Adrien Chauchet, et al.
British Journal of Haematology|July 4, 2019
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinibJorge J Castillo, Lian Xu, Joshua N Gustine, et al.
American Journal of Hematology|November 26, 2024
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Waldenström MacroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Pageof 33

Showing results (241-250 of 323) with videos related to

Sort By:
Pageof 33
Blood Advances|January 18, 2024
Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemiaKris Richardson, Jorge J Castillo, Shayna R Sarosiek, et al.
Plos One|October 5, 2018
Profiling of circulating exosomal miRNAs in patients with Waldenström MacroglobulinemiaJuliette M Bouyssou, Chia-Jen Liu, Mark Bustoros, et al.
Blood|January 18, 2006
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemiaSteven P Treon, Morie A Gertz, Meletios Dimopoulos, et al.
The Lancet. Haematology|October 22, 2020
Consensus treatment recommendations from the tenth International Workshop for Waldenström MacroglobulinaemiaJorge J Castillo, Ranjana H Advani, Andrew R Branagan, et al.
Haematologica|June 24, 2021
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapyJoshua N Gustine, Shayna Sarosiek, Catherine A Flynn, et al.
British Journal of Haematology|February 18, 2009
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom MacroglobulinemiaXavier Leleu, Zachary R Hunter, Lian Xu, et al.
European Journal of Haematology|March 12, 2008
Clinical relevance of soluble HLA class I molecules in Waldenstrom MacroglobulinemiaAnne-Sophie Moreau, Yasmine Sebti, Alain Duhamel, et al.
Blood|April 26, 2024
High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemiaEric Durot, Damien Roos-Weil, Adrien Chauchet, et al.
British Journal of Haematology|July 4, 2019
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinibJorge J Castillo, Lian Xu, Joshua N Gustine, et al.
American Journal of Hematology|November 26, 2024
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Waldenström MacroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Pageof 33